The pathways related to tumor progression, such as positive regulation of the MAPK cascade and FGFR (FGFR1, FGFR2, FGFR2c, FGFR3, and FGFR3c) ligand binding and activation, were significantly downregulated in the FSIP2-MT group (ES < 0, p < 0.05), suggesting a better efficacy. This evidence concerns the gene FGFR3 and neoplasm.